This clinical trial will be the first-in-Human (FiH) study of BAR 502.~This study is planned to investigate up to 4 dose levels of BAR 502. Each dose level will consist of 8 healthy male and female subjects (ratio 1:1, male: female) to have 6 subjects being administered BAR 502 and 2 subjects being administered placebo (ratio 3:1, active: placebo).~The study is designed to meet the following objectives:~Primary:~To evaluate the safety and tolerability of single-ascending doses of BAR 502 in healthy male and female subjects.~Secondary:~To investigate the pharmacokinetics (PK) of single-ascending doses of BAR 502 in healthy male and female subjects;~To investigate the pharmacodynamics (PD) of single-ascending doses of BAR 502 in healthy male and female subjects.
This is a prospective, single-center, randomized, double-blind, placebo-controlled, single-ascending dose (SAD) phase 1 study to evaluate the safety and tolerability of single-ascending doses of BAR 502 in healthy male and female subjects.